通过直接的分子相互作用,TDP-43通过延迟纤维细胞成熟来促进粉样β毒性
Adam J Gatch1,2, Feng Ding1
1Department of Physics and Astronomy, Clemson University, Clemson, South Carolina 29634, United States.
ACS chemical neuroscience
|July 29, 2024
概括
这项研究揭示了TAR DNA 结合蛋白 43 (TDP-43) 与氨基酸β (Aβ) 的相互作用. 结合TDP-43抑制了Aβ纤维的形成,可能会影响阿尔茨海默氏症.
科学领域:
- 神经科学是一个神经科学.
- 分子生物学分子生物学
- 计算生物学 计算生物学
背景情况:
- 粉样蛋白-β (Aβ) 形成粉样蛋白纤维,这是阿尔茨海默病 (AD) 病理学的特征.
- 塔尔DNA结合蛋白43 (TDP-43) 的错位化和聚合与神经退行性疾病有关.
- TDP-43与Aβ的相互作用可能会影响AD的发病,但分子机制尚不清楚.
研究的目的:
- 通过计算模拟来阐明Aβ和TDP-43之间的分子相互作用.
- 了解TDP-43结合如何影响Aβ自我组装和纤维细胞形成.
主要方法:
- 全原子离散分子动力学模拟.
- 计算型质阵列分析.
- 用Aβ40纤维细胞种子对TDP-43 N端域 (NTD) 的模拟.
主要成果:
- Aβ单体与TDP-43的NTD和RNA识别动机结合,促进β表形状.
- TDP-43的C端域在Aβ氨基原核中显示出强烈的相互作用.
- TDP-43 NTD与Aβ纤维的延长表面结合,以绝缘方式阻断单体添加.
结论:
- TDP-43通过物理阻断单体添加到纤维细胞种子来抑制Aβ纤维细胞的生长.
- 通过稳定寡合体状态和延迟纤维细胞成熟,TDP-43可能会增强Aβ毒性.
相关概念视频
Amyloid Fibrils
9.5K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
9.5K
Alzheimer's Disease: Overview
456
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
456
Alzheimer's Disease: Treatment
172
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
172


